This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (483)

Published on in Vol 3 , No 4 (2014) :Oct-Dec

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

Authors of this article:

Attyla Drabik 1 Author Orcid Image ;   Carina Hillgruber 2 Author Orcid Image ;   Tobias Goerge 2 Author Orcid Image
Article Authors Cited by (12) Tweetations (1) Metrics

Journals

  1. Renner R, Dissemond J, Goerge T, Hoff N, Kröger K, Erfurt-Berge C. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. Journal of the European Academy of Dermatology and Venereology 2017;31(11):1884 View
  2. Nakayama T, Mizutani K, Hanamura I, Kato H, Takami A, Takeshita K, Watanabe D. Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency. The Journal of Dermatology 2017;44(2):198 View
  3. Evans J, Jensen J, Sami N. Successful treatment of livedoid vasculopathy with rivaroxaban. JAAD Case Reports 2015;1(6):340 View
  4. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists. Actas Dermo-Sifiliográficas (English Edition) 2018;109(3):278 View
  5. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider S, Gerss J, Eveslage M, Drabik A, Goerge T. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology 2019;33(9):1784 View
  6. Franco Marques G, Criado P, Alves Batista Morita T, Cajas García M. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban. International Journal of Dermatology 2018;57(6):732 View
  7. Lee J, Kim I. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban. Clinical and Experimental Dermatology 2016;41(5):559 View
  8. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider S, Gerss J, Eveslage M, Drabik A, Goerge T. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. The Lancet Haematology 2016;3(2):e72 View
  9. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Vasculopatía livedoide tratada con rivaroxabán. Potenciales usos de los nuevos anticoagulantes orales para el dermatólogo. Actas Dermo-Sifiliográficas 2018;109(3):278 View
  10. Bilgic A, Ozcobanoglu S, Bozca B, Alpsoy E. Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management. International Journal of Women's Dermatology 2021;7(5):588 View
  11. Burg M, Mitschang C, Goerge T, Schneider S. Livedoid vasculopathy – A diagnostic and therapeutic challenge. Frontiers in Medicine 2022;9 View